From FDA Clearance to Global Adoption: LinaTech’s VenusX Sparked at ASTRO 2026


From September 26–30, the 68th Annual Meeting of the American Society for Radiation Oncology (ASTRO) was held in Boston. This year, LinaTech took the spotlight, showcasing pioneering radiotherapy advancements, that earned international recognition for its commitment to innovation.

 

Clinical Validation: VenusX Begins Clinical Use in the U.S.

Recently, The California Department of Public Health has officially approved LinaTech’s VenusX medical linear accelerator for clinical use.

 

图片1.png

 

Following FDA clearance and entering the Los Angeles market, VenusX is now fully deployed in clinical use in the U.S. This achievement confirms that LinaTech’s radiotherapy equipment is earning the trust of major healthcare systems and signals its expanding footprint in the Northern America and beyond.

 

ASTRO Engagement: Recognized by Global Experts

LinaTech has been a consistent presence at ASTRO for more than two decades, showcasing our evolving radiotherapy technologies over twenty years. This year, visitors came with purpose—exploring collaboration opportunities, discussing clinical applications, and evaluating pathways for integration into their radiotherapy programs. Such recognition cannot be achieved without nearly 30 years of relentless R&D, proven clinical validation, and ongoing product refinement.

 

图片2.png

 

At ASTRO 2026, VenusX unique Orthogonal Dual-layer MLC and advanced treatment technologies drew global attentions, earning recognitions for the clinical value and practical performance. VenusX didn’t just participate—it secured its place in global radiotherapy.

 

图片3.png

 

Market Adoption: Chosen in Competitive Markets

The strong interest at ASTRO reflects broader momentum: VenusX is gaining traction in competitive markets worldwide. Recent wins across South America and Africa highlight its ability to succeed in demanding procurement environments and meet the expectations of diverse clinical teams.

 

图片4.png

 

With regulatory approvals in 12 countries and regions, installations completed in 8, VenusX is rapidly expanding its global presence. LinaTech’s growth is driven not by isolated victories, but by sustained trust and proven performances.

 

LINK Alliance & Outlook: Connected for Global Access

Clinically proven, globally recognized, and chosen in competitive markets—this progress leads to the next phase: connection. The LINK Alliance brings radiotherapy professionals together, enabling hospitals to share expertise, elevate quality standards, and exchange operational know-how so advanced care reaches more patients.

 

From a single device to a global ecosystem, LinaTech is building a future where radiotherapy is more connected, more accessible, and more impactful. The mission remains clear: LINK a world where cancer is no longer an end of life, so every patient can look toward tomorrow with hope.

Recommended Reading

Hotline:+86 10 67888916

Time:8:00 - 18:00